Category Archives: Uncategorized

Drs. Tracy Macaulay and Liz Sulaica discuss hypertension. 0:00-0:45: Introduction 0:46-2:14: Intro of Dr. Liz Sulaica 2:15-4:19: SHEP Trial 4:20-6:19: Syst-Eur Trial 6:20-11:17: ALLHAT Trial 11:18-15:59: ACCOMPLISH Trial 16:00-18:53: HCTZ vs. Chlorthalidone 18:54-22:03: JNC 8 22:04-22:35: Closing References: SHEP Trial: SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons WithContinue reading “CardioScripts Classic – Hypertension [Part 1]”

Dr. Matthew Wanat and CardioScripts co-host, Dr. Liz Sulaica, discuss the ADAPTABLE trial.  0:00-0:25: Introduction  0:26-1:32: Introduction of Dr. Matthew Wanat 1:33-6:25: ADAPTABLE Overview  6:26-10:23: Aspirin Dosing and Overall Thoughts  10:24-12:06: Trial Limitations 12:07:-14:15: Literature and Guidelines for Aspirin in Primary Prevention (see additional references below) 14:16-18:11: Pragmatic Study Design 18:12-19:24: Final Thoughts  19:25-19:57: Closing  References:  ADAPTABLE: Jones WS, Mulder H,Continue reading “The ADAPTABLE Trial”

We are excited to announce our return to regular podcasting starting in June!

Dr. Ted Berei and CardioScripts co-host, Dr. Tracy Macaulay, discuss the EMPEROR-Reduced trial.  0:00-0:28: Introduction  0:29-1:05: Introduction of Dr. Ted Berei  1:06-3:40: EMPEROR-Reduced Overview  3:41-5:08: Overall Thoughts  5:09 -11:18: Secondary Endpoints  11:19-19:04: Considerations for Initiation of SGLT2 Inhibitors  19:05-21:21: Final Thoughts  21:22-22:02: Closing  References:  McMurray, John JV, et al. “Dapagliflozin in patients with heart failure and reduced ejection fraction.” New England Journal of Medicine 381.21 (2019): 1995-2008. Continue reading “EMPEROR-Reduced: Reign of the SGLT2 Inhibitors”

Dr. John Lindsley and CardioScripts co-host, Dr. Liz Sulaica, discuss cohort A of the POPular TAVI trial. 0:00-0:28: Introduction 0:29-1:04: Introduction of Dr. John Lindsley 1:05-6:12: Cohort A Overview 6:13-10:18: Overall Thoughts 10:19-12:30: Subclinical Valve Thrombosis 12:31-15:05: Management strategies 15:06-15:52: Final Thoughts 15:53-16:31: Closing References: POPular TAVI Trial [Cohort A]: Brouwer J, Nijenhuis VJ, DelewiContinue reading “POPular TAVI Trial [Cohort A]”

Dr. Toby Trujillo and CardioScripts co-host, Dr. Tracy Macaulay, discuss the LoDoCo2 trial. 0:00-027: Intro 0:28-1:03: Introduction of Dr. Toby Trujillo 1:04-4:10: LoDoCo2 Trial Overview 4:11-8:10: Overall Thoughts 8:11-9:49: Run-in period and tolerability 9:50-10:28: Monitoring and Infection 10:29-14:00: Fun New Game – Guess That Trial!! (hint – CURE and parallels to LoDoCo2) 14:01-14:59: Polypharmacy andContinue reading “The LoDoCo2 Trial”

Dr. Dave Dixon and CardioScripts co-host, Dr. Liz Sulaica, discuss the EVAPORATE trial and where icosapent ethyl fits. 0:00-0:27: Intro 0:28-1:09: Introduction of Dr. Dave Dixon 1:10-4:38: EVAPORATE Overview 4:39-6:12: Overall thoughts about EVAPORATE 6:13-9:23: Trial limitations 9:24-11:55: Isocapent ethyl in practice – involve the patient in decision-making! 11:56-14:31: How has practice changed since REDUCE-IT?Continue reading “The EVAPORATE Trial”

Dr. Robert DiDomenico and CardioScripts co-host, Dr. Tracy Macaulay, discuss the RATE AF trial and all things digoxin: its past role, therapeutic levels, and current and future state! 0:00-0:32 Intro 0:28-1:02: Welcome back and Introduction of Dr. DiDomenico 1:03-4:33: Overview of the RATE-AF trial as presented at ESC 2020 and based on published trial rationale.Continue reading “Digging into Dig[oxin]”

Dr. Ashley Schenk discusses mavacamten and obstructive hypertrophic cardiomyopathy. 0:00-0:28: Intro 0:29-1:09: Introduction of Dr. Ashley Schenk 1:10-5:55: Trial overview 5:56-8:36: Overview of obstructive hypertrophic cardiomyopathy 8:37-10:23: Pharmacological therapy used in patients with obstructive hypertrophic cardiomyopathy and why mavacamten is different 10:24-11:14: Initial thoughts about the trial 11:15-13:30: Beta-blocker subgroup analysis and disopyramide exclusion 13:31-15:05:Continue reading “HOCM POCM and Magical Mavacamten”

0:00-0:58: Intro 0:59-4:47: 1-year after ISAR-REACT 5, does prasugrel reign supreme? 4:48-7:32: Dr. Dunn and Dr. Macaulay dive into the confusing world of DAPT duration.  Who should get shorter and who get longer, based on DAPT trial, PEGASUS, TWILIGHT, TICO, and more.  7:33-10:46: When de-escalation is indicated, should it be aspirin or P2Y12 inhibitor thatContinue reading “CardioScripts Classic – Antiplatelets in ACS [Part 2]”